Illumina and Amgen-backed genomic sequencing technology developer Oxford Nanopore has added $59.6m to a round that now totals $98.1m.

OCD drug developer Exscientia bagged $60m in a Novo-led round that also featured Bristol-Myers Squibb and existing corporate investor Evotec.

Optum Ventures was among the investors as the mental health management app developer lifted its funding to $145m altogether.

Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.

The cancer, autoimmune and rare disease drug developer completed a $65m round that also featured MRL Ventures Fund and Cleva Pharma.

Access Industries' Access Biotechnology unit has contributed to a series A round for the paediatric oncology drug developer.

Stanford’s proteomic analysis spinout has lifted its funding haul beyond $100m with a round set to drive new hires and technology development.

Oxford Nanopore has added $59.6m to its latest funding round to bring the round to $98.1m and its overall funding to nearly $692m.

Nanoform has filed for a dual listing in Sweden and Finland, marking the first time that a University of Helsinki spinout is seeking an initial public offering.

The Mandatum Life and Ilmarinen-backed nanoparticle technology developer has priced a $76.7m offering that will take place in Sweden and Finland.